%0 Journal Article
%A Pavel, Marianne
%A Gross, David J
%A Benavent, Marta
%A Perros, Petros
%A Srirajaskanthan, Raj
%A Warner, Richard R P
%A Kulke, Matthew H
%A Anthony, Lowell B
%A Kunz, Pamela L
%A Hörsch, Dieter
%A Weickert, Martin O
%A Lapuerta, Pablo
%A Jiang, Wenjun
%A Kassler-Taub, Kenneth
%A Wason, Suman
%A Fleming, Rosanna
%A Fleming, Douglas
%A Garcia-Carbonero, Rocio
%T Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial.
%D 2018
%U http://hdl.handle.net/10668/12005
%X Telotristat ethyl, a tryptophan hydroxylase inhibitor, was efficacious and well tolerated in the phase 3 TELESTAR study in patients with carcinoid syndrome (CS) experiencing ≥4 bowel movements per day (BMs/day) while on somatostatin analogs (SSAs). TELECAST, a phase 3 companion study, assessed the safety and efficacy of telotristat ethyl in patients with CS (diarrhea, flushing, abdominal pain, nausea or elevated urinary 5-hydroxyindoleacetic acid (u5-HIAA)) with
%K 5-HIAA
%K carcinoid syndrome
%K metastatic neuroendocrine tumor
%K serotonin
%K somatostatin analog
%~